The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
Talquetamab will be administered subcutaneously (SC).
Other Name: JNJ-64407564
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC